MEDTRONIC VASCULAR GALWAY UNLIMITED COMPANY
Location
Founded
1989-12-19
Website
Risk Signals
4962 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Surgical and Medical Instruments and Apparatus, Drugs, Drug Proprietaries, and Druggists' Sundries), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about MEDTRONIC VASCULAR GALWAY UNLIMITED COMPANY
Live alerts from global media, monitored by Business Radar
2025-04-07 (thestandard.com.hk)
MOFCOM urges US firms to take 'practical measures' amid tariffs |
China's Ministry of Commerce met with more than 20 US enterprises on Sunday for Trump's tariffs, including representatives of Tesla, GE HealthCare and Medtronic.The MOFCOM hopes US firms &...
Read more
2023-06-14 (medicaldesignandoutsourcing.com)
How Medtronic's conflict minerals program investigates red flag suppliers
Medtronic's conflict minerals program looks deep into its supply chain to avoid inadvertently funding violence and human rights abuses.
Read more
2016-07-08 (ryortho.com)
NuVasive Pays Medtronic $45 Million Over Patent Dispute
NuVasive Pays Medtronic $45 Million Over Patent Dispute
Read more
2014-06-10 (ryortho.com)
Humana Accuses Medtronic of Infuse...
In a puzzling legal move Humana Inc. filed suit against Medtronic, Inc. and is trying to invoke the organized crime inspired RICO statute. Humana accuses Medtronic of conspiring with secretly paid surgeon agents to cook peer-review literature and then promote the off-label use of Infuse.
Read more
2005-04-25 (informa.com)
Medtronic settles spine patent dispute for $1.35bn
Medtronic has agreed to pay about $1.35bn to end patent litigation with Gary Michelson, the inventor of some of its spinal technologies. In the settlement deal, Medtronic will take ownership of more than 700 issued and pending US and foreign patents.
Read more